Cargando…
Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis
The addition of platinum compounds to standard neoadjuvant chemotherapy (NACT) for triple-negative breast cancer (TNBC) is highly controversial. Platinum agents, such as cisplatin and carboplatin, are DNA-damaging agents which exhibit activity in breast cancer, particularly in the TNBC subgroup. In...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652390/ https://www.ncbi.nlm.nih.gov/pubmed/34934456 http://dx.doi.org/10.3892/etm.2021.11014 |
_version_ | 1784611585127350272 |
---|---|
author | Vidra, Radu Nemes, Adina Vidrean, Andreea Pintea, Sebastian Tintari, Snejeana Deac, Andrada Ciuleanu, Tudor |
author_facet | Vidra, Radu Nemes, Adina Vidrean, Andreea Pintea, Sebastian Tintari, Snejeana Deac, Andrada Ciuleanu, Tudor |
author_sort | Vidra, Radu |
collection | PubMed |
description | The addition of platinum compounds to standard neoadjuvant chemotherapy (NACT) for triple-negative breast cancer (TNBC) is highly controversial. Platinum agents, such as cisplatin and carboplatin, are DNA-damaging agents which exhibit activity in breast cancer, particularly in the TNBC subgroup. In order to assess the efficacy of each most representative platinum agent (cisplatin and carboplatin) in patients with TNBC treated with NACT, the present study performed a systematic review and meta-analysis of all available published studies on TNBC. A search of PubMed was performed to identify studies that investigated platinum-based NACT in patients with TNBC. The primary endpoints were the pooled rate of the pathological complete response (pCR) between cisplatin vs. carboplatin-based NACT. A total of 24 studies were selected (17 studies for carboplatin and 6 studies for cisplatin and 1 study with both carboplatin and cisplatin, with 20 prospective studies) for the analysis of 1,711 patients with TNBC. Overall, the pooled rate of pCR in patients treated with platinum-based NACT was 48%. No significant differences were observed between the rates of pCR obtained under carboplatin vs cisplatin treatment. The carboplatin pCR rate was 0.470 [95% confidence interval (CI), 0.401-0.539], while the cisplatin pCR rate was 0.473 (95% CI, 0.379-0.568). The comparison between these two categories revealed no significant differences (P=0.959). In the whole, the present study demonstrates that neoadjuvant platinum-based chemotherapy improves the pCR rate in patients with TNBC, regardless of the platinum agent used. Carboplatin may thus represent a viable option due to its more favorable toxicity profile. |
format | Online Article Text |
id | pubmed-8652390 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-86523902021-12-20 Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis Vidra, Radu Nemes, Adina Vidrean, Andreea Pintea, Sebastian Tintari, Snejeana Deac, Andrada Ciuleanu, Tudor Exp Ther Med Articles The addition of platinum compounds to standard neoadjuvant chemotherapy (NACT) for triple-negative breast cancer (TNBC) is highly controversial. Platinum agents, such as cisplatin and carboplatin, are DNA-damaging agents which exhibit activity in breast cancer, particularly in the TNBC subgroup. In order to assess the efficacy of each most representative platinum agent (cisplatin and carboplatin) in patients with TNBC treated with NACT, the present study performed a systematic review and meta-analysis of all available published studies on TNBC. A search of PubMed was performed to identify studies that investigated platinum-based NACT in patients with TNBC. The primary endpoints were the pooled rate of the pathological complete response (pCR) between cisplatin vs. carboplatin-based NACT. A total of 24 studies were selected (17 studies for carboplatin and 6 studies for cisplatin and 1 study with both carboplatin and cisplatin, with 20 prospective studies) for the analysis of 1,711 patients with TNBC. Overall, the pooled rate of pCR in patients treated with platinum-based NACT was 48%. No significant differences were observed between the rates of pCR obtained under carboplatin vs cisplatin treatment. The carboplatin pCR rate was 0.470 [95% confidence interval (CI), 0.401-0.539], while the cisplatin pCR rate was 0.473 (95% CI, 0.379-0.568). The comparison between these two categories revealed no significant differences (P=0.959). In the whole, the present study demonstrates that neoadjuvant platinum-based chemotherapy improves the pCR rate in patients with TNBC, regardless of the platinum agent used. Carboplatin may thus represent a viable option due to its more favorable toxicity profile. D.A. Spandidos 2022-01 2021-11-26 /pmc/articles/PMC8652390/ /pubmed/34934456 http://dx.doi.org/10.3892/etm.2021.11014 Text en Copyright: © Vidra et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Vidra, Radu Nemes, Adina Vidrean, Andreea Pintea, Sebastian Tintari, Snejeana Deac, Andrada Ciuleanu, Tudor Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis |
title | Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis |
title_full | Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis |
title_fullStr | Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis |
title_full_unstemmed | Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis |
title_short | Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis |
title_sort | pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652390/ https://www.ncbi.nlm.nih.gov/pubmed/34934456 http://dx.doi.org/10.3892/etm.2021.11014 |
work_keys_str_mv | AT vidraradu pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis AT nemesadina pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis AT vidreanandreea pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis AT pinteasebastian pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis AT tintarisnejeana pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis AT deacandrada pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis AT ciuleanutudor pathologicalcompleteresponsefollowingcisplatinorcarboplatinbasedneoadjuvantchemotherapyfortriplenegativebreastcancerasystematicreviewandmetaanalysis |